泽璟制药：注射用ZG005、注射用ZGGS18与盐酸吉卡昔替尼片联用获得药物临床试验批准通知书

Core Viewpoint - ZaiJing Pharmaceutical (688266.SH) has received approval from the National Medical Products Administration for clinical trials of its innovative cancer immunotherapy products, ZG005 and ZGGS18, in combination with a specific drug for advanced solid tumors [1] Company Summary - ZG005 is a recombinant humanized bispecific antibody targeting PD-1/TIGIT, classified as a Class 1 innovative biopharmaceutical, with potential applications in treating various solid tumors [1] - ZG005 is one of the first drugs globally to enter clinical research targeting the same mechanism, with no similar mechanism drugs approved for market worldwide [1]